NEW YORK, June 9, 2008 (LAWFUEL) — The Brualdi Law Firm P.C.
announces that a lawsuit has commenced in the United States District
Court for the Western District of Wisconsin on behalf of purchasers of
TomoTherapy Inc. (“TomoTherapy” or “the Company”) (Nasdaq:TOMO) common
stock during the period between February 13, 2008 and April 17, 2008
(the “Class Period”).
No class has yet been certified in the above action. Until a class is
certified, you are not represented by counsel unless you retain one. If
you purchased TomoTherapy Inc. common stock during the period described
above, you have certain rights, and have until no later than 60 days
from July 29, 2008 in which to move for Lead Plaintiff status. Any
member of the purported class may move the Court to serve as lead
plaintiff through counsel of their choice, or may choose to do nothing
and remain an absent class member.
To be a member of the class you need not take any action at this time,
and you may retain counsel of your choice. If you wish to discuss this
action or have any questions concerning this Notice or your rights or
interests with respect to these matters, please contact Tali Leger,
Director of Shareholder Relations at The Brualdi Law Firm, 29 Broadway,
Suite 2400, New York, New York 10006, by telephone toll free at (877)
495-1877 or (212) 952-0602, by email to tleger@brualdilawfirm.com or
visit our website at http://www.brualdilawfirm.com/
The complaint alleges that, during the Class Period, the Company, and
certain of its officers and/or directors, violated federal securities
laws by withholding material facts from the investing public.
TomoTherapy develops markets and sells the Hi-Art system, is a
radiation therapy system for the treatment of various types of cancer.
As alleged in the complaint, defendants concealed in their February
Press Release that (a) a larger percentage of TomoTherapy’s revenue
backlog at December 31, 2007 and TomoTherapy’s new orders received
through February 12, 2008 were from for-profit entities which had
ordered multi-unit Hi-Art Systems and had scheduled deliveries of the
multi-units sequentially throughout 2008 and 2009; (b) the average
selling prices were lower in Q1’08 by approximately 11% than they had
been in Q1’07 because Q1’07 sales included a large number of European
sales denominated in Euros; (c) new sales orders from Europe had slowed
in Q1’08 through February 12, 2008 and TomoTherapy was experiencing a
serious delay in closing European orders; (d) TomoTherapy’s gross
margins in Q1’08 were and would continue to be approximately 20% lower
than they had been in Q1’07; and (e) TomoTherapy’s revenues in Q1’08
would be substantially lower and would not show increased growth from
either Q1’07 or Q4’07 and that TomoTherapy would suffer a loss in
Q1’08. Shortly after the February Release, director Neis sold
approximately 917,621 shares of TomoTherapy common stock during
February 26, 2008 through March 14, 2008.
